Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by IFP Advisors Inc

IFP Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 96.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,999 shares of the company’s stock after acquiring an additional 1,960 shares during the quarter. IFP Advisors Inc’s holdings in Teva Pharmaceutical Industries were worth $88,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 49.5% during the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after buying an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after buying an additional 2,204,623 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after buying an additional 569,412 shares during the period. State Street Corp raised its stake in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after buying an additional 1,778,268 shares during the period. Finally, AustralianSuper Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 16.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock worth $203,268,000 after buying an additional 1,329,319 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on TEVA shares. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Stock Up 1.4 %

Shares of TEVA opened at $15.91 on Thursday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a market capitalization of $18.03 billion, a PE ratio of -10.97, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The stock has a fifty day simple moving average of $19.15 and a two-hundred day simple moving average of $18.42. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.